We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
US Reclassifies Weed: Can Cannabis ETFs Give Your Portfolio a New High?
Read MoreHide Full Article
Key Takeaways
Cannabis firms likely to see stronger cash flows and balance sheets as 280E tax burdens are removed.
WEED rallied 84.3% over the past year, offering concentrated exposure to major U.S. cannabis firms.
YOLO gained over 56% in a year as cannabis rescheduling boosted growth expectations.
In a landmark policy shift, the Trump administration reclassified medical marijuana from a Schedule I to a Schedule III controlled substance in late April 2026, marking the most significant federal reform on cannabis in more than half a century. This historic pivot acknowledges the medical utility of cannabis, placing it alongside regulated drugs such as Tylenol with codeine and anabolic steroids, while stripping away its status as a “dangerous drug” comparable to heroin and LSD.
This reclassification has instantly put cannabis stocks back in the spotlight, along with the exchange-traded funds (ETFs) that hold them. These diversified investment vehicles may now serve as a primary gateway for investors seeking to capitalize on a regulatory barrier that has finally begun to break down.
To understand the significance of this development, it is necessary to explore the volatile history of cannabis companies and their related funds, the factors behind the reclassification, the growing role of cannabis in medicine, and the market opportunities that could emerge before examining the relevant ETFs in detail.
From Bust to Boom: The Rise of Weed
The journey of cannabis companies and their corresponding ETFs has been volatile. For years, the industry was hampered by "Schedule I" status, which prevented companies from deducting standard business expenses due to a tax code known as 280E. The persistent undercutting of prices by the illegal market also remained a major headwind. As a result, major cannabis ETFs have experienced significant outflows over the past couple of years.
The tide, however, began turning in mid-2025, when reports emerged that the federal government was seriously considering moving cannabis from Schedule I to Schedule III. Following a period of significant losses, marijuana ETFs began to rebound on the mere prospect of legalization and federal easing.
This momentum was further boosted by President Trump's visible support for cannabis reform, including a public endorsement of CBD for its health benefits and suggestions around Medicare coverage.
The April 2026 reclassification should now serve as a second accelerant, with its primary benefit being the removal of the 280E tax burden. With rescheduling, cannabis companies registered under state medical programs will, for the first time, be able to deduct standard business costs, which should significantly boost their cash flows and balance sheets. Thus, for cannabis-focused ETFs, this represents a potential “lift-off” moment, as a surge in cannabis companies’ net income could strengthen fund assets and make them far more attractive to institutional investors.
The rationale behind this latest reclassification is rooted in science and public health. Federal health agencies have finally recognized that cannabis has a "currently accepted medical use," particularly in managing chronic pain, epilepsy, and nausea associated with chemotherapy. By moving it to Schedule III, the government is acknowledging its role as a therapeutic tool rather than a street narcotic.
Is the Grass Greener Ahead for Weed?
The latest reclassification eases longstanding barriers to scientific research by opening the door to broader and more rigorous investigation of cannabis’ medical potential, including its well-documented use in managing chronic pain, PTSD, epilepsy, and neurological disorders.
To this end, it is imperative to mention that the DEA has additionally scheduled a broader rescheduling hearing for June 29, 2026, which could extend Schedule III status beyond medical marijuana to cannabis more broadly.
Of course, the reclassification does not resolve every challenge, as cannabis firms still operate in a fragmented, state-by-state regulatory environment, banking access remains restricted, and many U.S. marijuana companies continue to list on Canadian exchanges or trade over the counter. However, improved cash flow from rescheduling could strengthen the financial position of cannabis companies, with the June DEA hearing likely to help determine how far and how quickly this momentum progresses.
Based on these, the outlook for the cannabis market remains solid. As per Grand View Research, the global medical marijuana market could reach $65.8 billion by 2030, at a CAGR of 21.8%, propelled by rising clinical adoption and growing physician willingness to recommend cannabinoid therapies.
4 Cannabis ETFs Worth Watching
Considering the discussion above, investors seeking to capture the rising momentum of the cannabis market through diversified exposure may consider adding the following ETFs to their watchlist:
It is the first actively managed U.S.-listed ETF with dedicated cannabis exposure, focusing exclusively on U.S. companies, including multi-state operators. Curaleaf Holdings enjoys the first spot in this fund, with 10.50% weightage.
MSOS has surged 73.6% over the past year. The fund charges 78 basis points (bps) as fees.
It is an active fund that offers exposure to U.S. companies which operate across the cannabis ecosystem. Trulieve Cannabis enjoys the first spot in this fund, with 18.47% weightage.
CNBS has surged 56.4% over the past year. The fund charges 76 bps as fees.
It offers concentrated exposure to the largest U.S. cannabis companies. Curaleaf Holdings enjoys the first spot in this fund, with 36.82% weightage.
WEED has rallied 84.3% over the past year. This fund charges 41 bps as gross expense ratio, while its net expense ratio is 0.00%. (Investors should note that fee waivers for WEED are contractual and in effect until at least May 1, 2026, per the issuer)
It seeks growth opportunities by investing in equities of U.S. and foreign cannabis-related companies engaging in legal business. AdvisorShares Pure US Cannabis ETF enjoys the first spot in this fund, with 47.09% weightage.
YOLO has gained 57.2% over the past year. The fund charges 51 bps as fees.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
US Reclassifies Weed: Can Cannabis ETFs Give Your Portfolio a New High?
Key Takeaways
In a landmark policy shift, the Trump administration reclassified medical marijuana from a Schedule I to a Schedule III controlled substance in late April 2026, marking the most significant federal reform on cannabis in more than half a century. This historic pivot acknowledges the medical utility of cannabis, placing it alongside regulated drugs such as Tylenol with codeine and anabolic steroids, while stripping away its status as a “dangerous drug” comparable to heroin and LSD.
This reclassification has instantly put cannabis stocks back in the spotlight, along with the exchange-traded funds (ETFs) that hold them. These diversified investment vehicles may now serve as a primary gateway for investors seeking to capitalize on a regulatory barrier that has finally begun to break down.
To understand the significance of this development, it is necessary to explore the volatile history of cannabis companies and their related funds, the factors behind the reclassification, the growing role of cannabis in medicine, and the market opportunities that could emerge before examining the relevant ETFs in detail.
From Bust to Boom: The Rise of Weed
The journey of cannabis companies and their corresponding ETFs has been volatile. For years, the industry was hampered by "Schedule I" status, which prevented companies from deducting standard business expenses due to a tax code known as 280E. The persistent undercutting of prices by the illegal market also remained a major headwind. As a result, major cannabis ETFs have experienced significant outflows over the past couple of years.
The tide, however, began turning in mid-2025, when reports emerged that the federal government was seriously considering moving cannabis from Schedule I to Schedule III. Following a period of significant losses, marijuana ETFs began to rebound on the mere prospect of legalization and federal easing.
This momentum was further boosted by President Trump's visible support for cannabis reform, including a public endorsement of CBD for its health benefits and suggestions around Medicare coverage.
The April 2026 reclassification should now serve as a second accelerant, with its primary benefit being the removal of the 280E tax burden. With rescheduling, cannabis companies registered under state medical programs will, for the first time, be able to deduct standard business costs, which should significantly boost their cash flows and balance sheets. Thus, for cannabis-focused ETFs, this represents a potential “lift-off” moment, as a surge in cannabis companies’ net income could strengthen fund assets and make them far more attractive to institutional investors.
The rationale behind this latest reclassification is rooted in science and public health. Federal health agencies have finally recognized that cannabis has a "currently accepted medical use," particularly in managing chronic pain, epilepsy, and nausea associated with chemotherapy. By moving it to Schedule III, the government is acknowledging its role as a therapeutic tool rather than a street narcotic.
Is the Grass Greener Ahead for Weed?
The latest reclassification eases longstanding barriers to scientific research by opening the door to broader and more rigorous investigation of cannabis’ medical potential, including its well-documented use in managing chronic pain, PTSD, epilepsy, and neurological disorders.
To this end, it is imperative to mention that the DEA has additionally scheduled a broader rescheduling hearing for June 29, 2026, which could extend Schedule III status beyond medical marijuana to cannabis more broadly.
Of course, the reclassification does not resolve every challenge, as cannabis firms still operate in a fragmented, state-by-state regulatory environment, banking access remains restricted, and many U.S. marijuana companies continue to list on Canadian exchanges or trade over the counter. However, improved cash flow from rescheduling could strengthen the financial position of cannabis companies, with the June DEA hearing likely to help determine how far and how quickly this momentum progresses.
Based on these, the outlook for the cannabis market remains solid. As per Grand View Research, the global medical marijuana market could reach $65.8 billion by 2030, at a CAGR of 21.8%, propelled by rising clinical adoption and growing physician willingness to recommend cannabinoid therapies.
4 Cannabis ETFs Worth Watching
Considering the discussion above, investors seeking to capture the rising momentum of the cannabis market through diversified exposure may consider adding the following ETFs to their watchlist:
AdvisorShares Pure US Cannabis ETF (MSOS - Free Report)
It is the first actively managed U.S.-listed ETF with dedicated cannabis exposure, focusing exclusively on U.S. companies, including multi-state operators. Curaleaf Holdings enjoys the first spot in this fund, with 10.50% weightage.
MSOS has surged 73.6% over the past year. The fund charges 78 basis points (bps) as fees.
Amplify Seymour Cannabis ETF (CNBS - Free Report)
It is an active fund that offers exposure to U.S. companies which operate across the cannabis ecosystem. Trulieve Cannabis enjoys the first spot in this fund, with 18.47% weightage.
CNBS has surged 56.4% over the past year. The fund charges 76 bps as fees.
Roundhill Cannabis ETF (WEED - Free Report)
It offers concentrated exposure to the largest U.S. cannabis companies. Curaleaf Holdings enjoys the first spot in this fund, with 36.82% weightage.
WEED has rallied 84.3% over the past year. This fund charges 41 bps as gross expense ratio, while its net expense ratio is 0.00%. (Investors should note that fee waivers for WEED are contractual and in effect until at least May 1, 2026, per the issuer)
AdvisorShares Pure Cannabis ETF (YOLO - Free Report)
It seeks growth opportunities by investing in equities of U.S. and foreign cannabis-related companies engaging in legal business. AdvisorShares Pure US Cannabis ETF enjoys the first spot in this fund, with 47.09% weightage.
YOLO has gained 57.2% over the past year. The fund charges 51 bps as fees.